Oncolytics Biotech says study shows pelareorep triggers immune activation in liver cancer
ONCY•Oncolytics Biotech highlighted a peer-reviewed publication dated Sept. 28, 2026, reporting preclinical findings that pelareorep may activate immune responses in liver tumors and improve sensitivity to immunotherapy.
1. Preclinical findings
The publication describes preclinical findings that pelareorep can shift liver tumors toward immune activity, potentially improving responsiveness to immunotherapy. Management framed the data as supporting pelareorep’s broader combination strategy, not as a move to pursue liver cancer as an indication.
